An Introduction to Haematology
The field of haematology is far-reaching, encompassing many conditions of the blood and blood-forming organs, including anaemia, bleeding and coagulation disorders, sickle cell disease, congenital immunodeficiency diseases, transfusion medicine and haematopoietic stem cell transplantation. There continue to be many obstacles to gene therapy but ultimately this approach holds promise in inherited blood disorders. In addition, novel anticoagulant therapies, multiplexed sensing platforms and the application of artificial intelligence in diagnosis and monitoring are proving valuable in clotting disorders.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease
Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study […]
Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease – Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials
Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of […]
Saskia Middeldorp, ASH 2022: The efficacy of low-molecular-weight heparin in women with recurrent miscarriage and inherited thrombophilia – the ALIFE 2 trial
Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with Professor Saskia Middeldorp (Radboud University Medical Center, Nijmegen, Netherlands) to discuss the ALIFE 2 clinical trial and the […]
Sutimlimab for the Treatment of Cold Agglutinin Disease
touchREVIEWS in Oncology & Haematology. 2022;19(1):Online ahead of journal publication
In recent years, our understanding of the complement system and its role in disease has increased dramatically. With the advent of complement 5 (C5) and C3 inhibitors, our ability to manipulate the complement system has improved the outcomes and quality of life for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic–uraemic syndrome.1–3 More recently, this understanding […]
Facing clinical challenges associated with paroxysmal nocturnal haemoglobinuria
Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.
- Summarize the signs and symptoms of PNH and how these inform the clinical diagnosis
- Explain the benefits and limitations of current and emerging complement inhibitor therapies for PNH
- Explain the burden of PNH and impact on patients’ quality of life
Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy
Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.
- Discuss the treatment for patients with CML after two prior lines of therapy in clinical practice
- Recall the latest clinical trial data for new and emerging treatments for patients with CML
- Evaluate the possible impact of new and emerging treatments on the management of patients with CML after two prior lines of therapy
Getting personal: Individualizing therapy for cold agglutinin disease
Watch two experts give their perspectives on the recommended workup for a timely and accurate diagnosis, as well as the evolving treatment landscape, and the importance of individualizing therapy for patients with cold agglutinin disease.
- Outline strategies for the accurate diagnosis of cold agglutinin disease
- Evaluate the current and emerging treatment options for patients with cold agglutinin disease using the latest data
- Assess potential strategies for individualizing the treatment for patients with cold agglutinin disease
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
Watch three experts discuss the pathophysiology of cold agglutinin disease (CAD) and the steps needed for an accurate diagnosis. The panel goes on to discuss how emerging treatment options are changing the management of patients with primary CAD and the importance of tailoring treatment to improve outcomes. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.
- Describe the immunopathogenesis of cold agglutinin disease (CAD) and implications for effective patient management
- Appraise current and emerging treatment options for patients with CAD using the latest data
- Evaluate strategies to individualize the treatment and management of patients with CAD
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!